ChiCTR2400083779 版本V1.0 版本创建时间2024/04/30 22:49:31 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400083779 

最近更新日期:

Date of Last Refreshed on:

2024-04-30 22:49:17 

注册时间:

Date of Registration:

2024-04-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

活血通络起痿汤治疗糖尿病性勃起功能障碍的临床研究

Public title:

Clinical study of Huoxue TongLuo QiWei Prescription on Diabetic Erectile Dysfunction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

活血通络起痿汤治疗糖尿病性勃起功能障碍的临床研究

Scientific title:

Clinical study of Huoxue TongLuo QiWei Prescription on Diabetic Erectile Dysfunction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王景尚 

研究负责人:

王景尚 

Applicant:

Wang JingShang 

Study leader:

Wang JingShang 

申请注册联系人电话:

Applicant telephone:

+86 18811213525

研究负责人电话:

Study leader's telephone:

+86 10 52276423

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangjingshang108325@126.com

研究负责人电子邮件:

Study leader's E-mail:

18811213525@139.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区姚家园路251号

研究负责人通讯地址:

姚家园路251号

Applicant address:

251 Yaojiayuan Road, Chaoyang District, Beijing

Study leader's address:

251 Yao Jiayuan Road, Chaoyang District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京妇产医院

Applicant's institution:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

研究负责人所在单位:

北京妇产医院、首都医科大学附属北京妇产医院、北京妇幼保健院

Affiliation of the Leader:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-KY-040-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京妇产医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Community,Beijing Obstetrics and Gynecology Hospital,Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-04-11 00:00:00

伦理委员会联系人:

才汗

Contact Name of the ethic committee:

Cai Han

伦理委员会联系地址:

姚家园路251号

Contact Address of the ethic committee:

251 Yao Jiayuan Road, Chaoyang District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 85968407

伦理委员会联系人邮箱:

Contact email of the ethic committee:

saihan1678@163.com

研究实施负责(组长)单位:

北京妇产医院、首都医科大学附属北京妇产医院、北京妇幼保健院

Primary sponsor:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

研究实施负责(组长)单位地址:

姚家园路251号

Primary sponsor's address:

251 Yao Jiayuan Road, Chaoyang District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京妇产医院、首都医科大学附属北京妇产医院、北京妇幼保健院

具体地址:

姚家园路251号

Institution
hospital:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

Address:

251 Yao Jiayuan Road, Chaoyang District, Beijing, China

经费或物资来源:

首都卫生发展科研专项

Source(s) of funding:

Capital’s Funds for Health Improvement and Research

Target disease:

Diabetic erectile dysfunction

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

①明确活血通络起痿汤联合小剂量他达拉非治疗糖尿病性勃起功能障碍的临床有效性及安全性; ②为活血通络起痿汤的临床推广应用提供科学依据。  

Objectives of Study:

① To determine the clinical efficacy and safety of Huoxue Tongluo Qiwei Decoction combined with low-dose tadalafil in the treatment of diabetic erectile dysfunction; ② To provide scientific basis for the clinical promotion and application of Huoxue Tongluo Qiwei Tang.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合糖尿病和勃起功能障碍的西医诊断标准者,且勃起功能障碍诊断在糖尿病之后;;
2.血糖已控制在较好水平,且持续时间在1个月以上:FPG≤7.0 mmol/L,餐后2hPG≤10.0 mmol/L;;
3.符合糖尿病勃起功能障碍及血瘀证中医诊断标准者;
4.20≤年龄≤60岁的男性,具备同条件,性欲正常;;
5.已自愿签署知情同意书者;;

Inclusion criteria

1.Those who meet the diagnostic criteria of western medicine for diabetes and erectile dysfunction, and whose erectile dysfunction is diagnosed after diabetes;;
2.Blood glucose has been controlled at a good level and lasts for more than one month: FPG ≤ 7.0 mmol/L, postprandial PG ≤ 10.0 mmol/L;
3.Those who meet the diagnostic criteria of diabetic erectile dysfunction and Blood stasis syndrome of traditional Chinese medicine;
4.Men aged 20 ≤ 60, with the same conditions and normal sexual desire;
5.Those who have voluntarily signed the informed consent form;

排除标准:

1.合并严重心血管疾病、脑血管疾病,肝肾功能不全、造血系统疾病,神经病患者;;
2.合并尿道炎、急性前列腺炎、泌尿系结石等疾病;
3.盆腔手术史或6个月内有进行手术者;;
4.长期服用利尿药、降压药、镇静药、抗抑郁药、激素类及相关药物者;

Exclusion criteria:

1.Patients with severe cardiovascular disease, cerebrovascular disease, liver and kidney dysfunction, hematopoietic system diseases, and neurological disorders;;
2.Concomitant diseases such as urethritis, acute prostatitis, and urinary tract stones;
3.History of pelvic surgery or those who have undergone surgery within 6 months;
4.Long term use of diuretics, antihypertensive drugs, sedatives, antidepressants, steroids, and related medications;

研究实施时间:

Study execute time:

From 2024-01-02 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-05-01 00:00:00 To 2026-09-30 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

81

Group:

control group

Sample size:

干预措施:

他达拉非

干预措施代码:

Intervention:

Tadalafil

Intervention code:

组别:

治疗组

样本量:

81

Group:

Treatment group

Sample size:

干预措施:

活血通络起痿汤+他达拉非

干预措施代码:

Intervention:

Huoxue Tongluo Qiwei Tang+Tadalafil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京妇产医院、首都医科大学附属北京妇产医院、北京妇幼保健院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京中医药大学东直门医院 

单位级别:

三级甲等 

Institution
hospital:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

IIEF-5评分

指标类型:

主要指标

Outcome:

IIEF-5 rating

Type:

Primary indicator

测量时间点:

0周,4周,8周,12周

测量方法:

使用IIEF-5评分表进行测量

Measure time point of outcome:

0 weeks, 4 weeks, 8 weeks, 12 weeks

Measure method:

Measure using the IIEF-5 rating scale

指标中文名:

性生活质量改善评分

指标类型:

次要指标

Outcome:

Quality of sexual life improvement score

Type:

Secondary indicator

测量时间点:

0周,4周,8周,12周

测量方法:

患者填写mSLQQ-QoL调差表,并进行评分

Measure time point of outcome:

0 weeks, 4 weeks, 8 weeks, 12 weeks

Measure method:

The patient fills out the mSLQQ-QoL adjustment form and scores it

指标中文名:

中医症状积分

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine Symptom Score

Type:

Secondary indicator

测量时间点:

0周,4周,8周,12周

测量方法:

应用中医症状量表进行测量

Measure time point of outcome:

0 weeks, 4 weeks, 8 weeks, 12 weeks

Measure method:

Applying Traditional Chinese Medicine Symptom Scale for Measurement

指标中文名:

性生活情况

指标类型:

次要指标

Outcome:

Sexual activity

Type:

Secondary indicator

测量时间点:

0周,4周,8周,12周

测量方法:

患者自行填写性生活频率调查表,主要包括每周性交次数及成功性交次数。

Measure time point of outcome:

0 weeks, 4 weeks, 8 weeks, 12 weeks

Measure method:

The patient fills out a sexual activity frequency questionnaire on their own, which mainly includes the frequency of sexual intercourse per week and the number of successful sexual encounters.

指标中文名:

血糖

指标类型:

次要指标

Outcome:

blood glucose

Type:

Secondary indicator

测量时间点:

0周,4周,8周,12周

测量方法:

入组前需测一次静脉血糖以筛选符合纳入标准患者,纳入患者治疗过程中每3天需测一次指尖空腹及餐后2小时血糖,每2周测一次静脉空腹及餐后2小时血糖以评估血糖达标情况,必要时建议患者退出试验进行进一步血糖控制。治疗前后测定糖化血红蛋白水平。

Measure time point of outcome:

0 weeks, 4 weeks, 8 weeks, 12 weeks

Measure method:

Before enrollment, venous blood glucose should be measured once to screen patients who meet the inclusion criteria. During the treatment process, fingertip fasting and 2-hour postprandial blood glucose should be measured every 3 days, and venous fasting and 2-hour postprandial blood glucose should be measured every 2 weeks to evaluate blood glucose compliance. If necessary, it is recommended that patients withdraw from the trial for further blood glucose control. Measure glycated hemoglobin leve

指标中文名:

性激素

指标类型:

次要指标

Outcome:

sex hormone

Type:

Secondary indicator

测量时间点:

0周,4周,8周,12周

测量方法:

采血测性激素五项(T、E2、FSH、LH、PRL)水平。(每4周)

Measure time point of outcome:

0 weeks, 4 weeks, 8 weeks, 12 weeks

Measure method:

Blood was collected to measure the levels of five sex hormones (T, E2, FSH, LH, PRL).

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 60 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

由第三方统计人员运用SPSS统计软件,采用随机数字表法生成随机方案

Randomization Procedure (please state who generates the random number sequence and by what method):

Generate a random plan using the random number table method using SPSS statistical software by third-party statisticians

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲,对评估者隐藏分组

Blinding:

Single blind study with blinded-evaluators

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验结束后6个月,在临床试验公共管理平台ResMan 网站共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

6 months after the end of the trial, share on the ResMan website of the clinical trial public management platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(CRF)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form(CRF)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-04-30 22:49:17